CHDI
Listed here are over 1000 publications that describe some of the research funded (in whole or in part) by CHDI Foundation. You can also view just the subset of publications that have CHDI staff as authors.
Publication Search
Title
Journal
Paulsen JS, Long JD, Johnson HJ, Aylward EH, Ross CA, Williams JK, Nance MA, Erwin CJ, Westervelt HJ, Harrington DL, Bockholt HJ, Zhang Y, McCusker EA, Chiu EM, Panegyres PK, Predict-Hd Investigators, Coordinators of the Huntington Study Group
Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: A decade of the PREDICT-HD study
Beaumont V, Park L, Rassoulpour A, Dijkman U, Heikkinen T, Lehtimaki K, Kontkanen O, Al Nackkash R, Bates GP, Gleyzes M, Steidl E, Ramboz S, Murphy C, Beconi MG, Dominguez C, Munoz-Sanjuan I
The PDE1/5 inhibitor SCH-51866 does not modify disease progression in the R6/2 mouse model of Huntington`s Disease
Todd D, Gowers I, Dowler SJ, Wall MD, McAllister G, Fischer DF, Dijkstra S, Fratantoni SA, van de Bospoort R, Veenman-Koepke J, Flynn G, Arjomand J, Dominguez C, Munoz-Sanjuan I, Wityak J, Bard JA
A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington`s disease
Burli RW, Luckhurst CA, Aziz O, Matthews KL, Yates D, Lyons KA, Beconi M, McAllister G, Breccia P, Stott AJ, Penrose SD, Wall M, Lamers M, Leonard P, Muller I, Richardson CM, Jarvis R, Stones L, Hughes S, Wishart G, Haughan AF, O`Connell C, Mead T, McNeil H, Vann J, Mangette J, Maillard M, Beaumont V, Munoz-Sanjuan I, Dominguez C
Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington`s disease
Träger U, Magnusson A, Lahiri Swales N, Wild E, North J, Lowdell M, Björkqvist M
JAK/STAT signalling in Huntington's disease immune cells
Franciosi S, Shim Y, Lau M, Hayden MR, Leavitt BR
A systematic review and meta-analysis of clinical variables used in Huntington disease research
Dorsey ER, Brocht AF, Nichols PE, Darwin KC, Anderson KE, Beck CA, Singh S, Biglan KM, Shoulson I
Depressed mood and suicidality in individuals exposed to tetrabenazine in a large Huntington disease observational study
Crawford HE, Hobbs NZ, Keogh R, Langbehn DR, Frost C, Johnson H, Landwehrmeyer B, Reilmann R, Craufurd D, Stout JC, Durr A, Leavitt BR, Roos RA, Tabrizi SJ, Scahill RI, TRACK-HD Investigators
Corpus callosal atrophy in premanifest and early Huntington's disease
Deng YP, Wong T, Bricker-Anthony C, Deng B, Reiner A
Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington's disease mice
Busan S, Weeks KM
Role of context in RNA structure: flanking sequences reconfigure CAG motif folding in huntingtin exon 1 transcripts
Biochemistry
November 19, 2013
52 (46) :8219-25
52 (46) :8219-25
PMID: 24199621
PMCID: 4890576
DOI: 10.1021/bi401129r
Sawiak SJ, Wood NI, Williams GB, Morton AJ, Carpenter TA
Voxel-based morphometry with templates and validation in a mouse model of Huntington's disease
Paulsen JS, Smith MM, Long JD, PREDICT HD investigators and Coordinators of the Huntington Study Group
Cognitive decline in prodromal Huntington Disease: implications for clinical trials
Gipson TA, Neueder A, Wexler NS, Bates GP, Housman D
Aberrantly spliced HTT, a new player in Huntington's disease pathogenesis
Mielcarek M, Landles C, Weiss A, Bradaia A, Seredenina T, Inuabasi L, Osborne GF, Wadel K, Touller C, Butler R, Robertson J, Franklin SA, Smith DL, Park L, Marks PA, Wanker EE, Olson EN, Luthi-Carter R, van der Putten H, Beaumont V, Bates GP
HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration
Elble R, Bain P, Forjaz MJ, Haubenberger D, Testa C, Goetz CG, Leentjens AF, Martinez-Martin P, Pavy-Le Traon A, Post B, Sampaio C, Stebbins GT, Weintraub D, Schrag A
Task force report: scales for screening and evaluating tremor: critique and recommendations
Wójtowicz AM, Dvorzhak A, Semtner M, Grantyn R
Reduced tonic inhibition in striatal output neurons from Huntington mice due to loss of astrocytic GABA release through GAT-3
Ellison SM, Trabalza A, Tisato V, Pazarentzos E, Lee S, Papadaki V, Goniotaki D, Morgan S, Mirzaei N, Mazarakis ND
Dose-dependent neuroprotection of VEGF₁₆₅ in Huntington's disease striatum
Aylward EH, Harrington DL, Mills JA, Nopoulos PC, Ross CA, Long JD, Liu D, Westervelt HK, Paulsen JS, PREDICT-HD Investigators and Coordinators of the Huntington Study Group
Regional atrophy associated with cognitive and motor function in prodromal Huntington disease
J Huntingtons Dis
October 1, 2013
2 (4) :477-89
2 (4) :477-89
PMID: 25062732
PMCID: 4412155
DOI: 10.3233/JHD-130076
Liu J, Pendergraff H, Narayanannair KJ, Lackey JG, Kuchimanchi S, Rajeev KG, Manoharan M, Hu J, Corey DR
RNA duplexes with abasic substitutions are potent and allele-selective inhibitors of huntingtin and ataxin-3 expression
Nucleic Acids Res
October 1, 2013
41 (18) :8788-801
41 (18) :8788-801
PMID: 23887934
PMCID: 3794577
DOI: 10.1093/nar/gkt594
Mason RP, Casu M, Butler N, Breda C, Campesan S, Clapp J, Green EW, Dhulkhed D, Kyriacou CP, Giorgini F
Glutathione peroxidase activity is neuroprotective in models of Huntington's disease
Georgiou-Karistianis N, Poudel GR, Dominguez DJf, Langmaid R, Gray MA, Churchyard A, Chua P, Borowsky B, Egan GF, Stout JC
Functional and connectivity changes during working memory in Huntington`s disease: 18 month longitudinal data from the IMAGE-HD study
Epping EA, Mills JA, Beglinger LJ, Fiedorowicz JG, Craufurd D, Smith MM, Groves M, Bijanki KR, Downing N, Williams JK, Long JD, Paulsen JS, Predict-Hd Investigators, Coordinators of the Huntington Study Group
Characterization of depression in prodromal Huntington disease in the neurobiological predictors of HD (PREDICT-HD) study
Moscovitch-Lopatin M, Goodman RE, Eberly S, Ritch JJ, Rosas HD, Matson S, Matson W, Oakes D, Young AB, Shoulson I, Hersch SM, Huntington Study Group PHAROS Investigators
HTRF analysis of soluble huntingtin in PHAROS PBMCs
McCusker EA, Gunn DG, Epping EA, Loy CT, Radford K, Griffith J, Mills JA, Long JD, Paulsen JS, PREDICT-HD Investigators of the Huntington Study Group
Unawareness of motor phenoconversion in Huntington disease
Domínguez D JF, Egan GF, Gray MA, Poudel GR, Churchyard A, Chua P, Stout JC, Georgiou-Karistianis N
Multi-modal neuroimaging in premanifest and early Huntington's disease: 18 month longitudinal data from the IMAGE-HD study
Sbodio JI, Paul BD, Machamer CE, Snyder SH
Golgi protein ACBD3 mediates neurotoxicity associated with Huntington's disease
Lee CY, Cantle JP, Yang XW
Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis
Tang CC, Feigin A, Ma Y, Habeck C, Paulsen JS, Leenders KL, Teune LK, van Oostrom JC, Guttman M, Dhawan V, Eidelberg D
Metabolic network as a progression biomarker of premanifest Huntington's disease
J Clin Invest
September 2, 2013
123 (9) :4076-88
123 (9) :4076-88
PMID: 23985564
PMCID: 3754266
DOI: 10.1172/JCI69411
Maillard MC, Dominguez C, Gemkow MJ, Krieger F, Park H, Schaertl S, Winkler D, Munoz-Sanjuan I
A label-free LC/MS/MS-based enzymatic activity assay for the detection of genuine caspase inhibitors and SAR development
Winkler D, Beconi M, Toledo-Sherman LM, Prime M, Ebneth A, Dominguez C, Munoz-Sanjuan I
Development of LC/MS/MS, high-throughput enzymatic and cellular assays for the characterization of compounds that inhibit kynurenine monooxygenase (KMO)
Delmaire C, Dumas EM, Sharman MA, van den Bogaard SJ, Valabregue R, Jauffret C, Justo D, Reilmann R, Stout JC, Craufurd D, Tabrizi SJ, Roos RA, Durr A, Lehericy S
The structural correlates of functional deficits in early huntington`s disease
Lee JM, Galkina EI, Levantovsky RM, Fossale E, Anne Anderson M, Gillis T, Srinidhi Mysore J, Coser KR, Shioda T, Zhang B, Furia MD, Derry J, Kohane IS, Seong IS, Wheeler VC, Gusella JF, MacDonald ME
Dominant effects of the Huntington`s disease HTT CAG repeat length are captured in gene-expression data sets by a continuous analysis mathematical modeling strategy
Hum Mol Genet
August 15, 2013
22 (16) :3227-38
22 (16) :3227-38
PMID: 23595883
PMCID: PMC3723309
DOI: 10.1093/hmg/ddt176
Marco S, Giralt A, Petrovic MM, Pouladi MA, Martínez-Turrillas R, Martínez-Hernández J, Kaltenbach LS, Torres-Peraza J, Graham RK, Watanabe M, Luján R, Nakanishi N, Lipton SA, Lo DC, Hayden MR, Alberch J, Wesseling JF, Pérez-Otaño I
Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington's disease models
Divino V, Dekoven M, Warner JH, Giuliano J, Anderson KE, Langbehn D, Lee WC
The direct medical costs of Huntington`s disease by stage. A retrospective commercial and Medicaid claims data analysis
Bonner-Jackson A, Long JD, Westervelt H, Tremont G, Aylward E, Paulsen JS, Predict-Hd Investigators, Coordinators of the Huntington Study Group
Cognitive reserve and brain reserve in prodromal Huntington`s disease
Delli Carri A, Onorati M, Castiglioni V, Faedo A, Camnasio S, Toselli M, Biella G, Cattaneo E
Human pluripotent stem cell differentiation into authentic striatal projection neurons
O’Rourke JG, Gareau JR, Ochaba J, Song W, Raskó T, Reverter D, Lee J, Monteys AM, Pallos J, Mee L, Vashishtha M, Apostol BL, Nicholson TP, Illes K, Zhu YZ, Dasso M, Bates GP, Difiglia M, Davidson B, Wanker EE, Marsh JL, Lima CD, Steffan JS, Thompson LM
SUMO-2 and PIAS1 modulate insoluble mutant huntingtin protein accumulation
Chen JY, Wang EA, Cepeda C, Levine MS
Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility
Kantor S, Szabo L, Varga J, Cuesta M, Morton AJ
Progressive sleep and electroencephalogram changes in mice carrying the Huntington's disease mutation
Fisher SP, Black SW, Schwartz MD, Wilk AJ, Chen TM, Lincoln WU, Liu HW, Kilduff TS, Morairty SR
Longitudinal analysis of the electroencephalogram and sleep phenotype in the R6/2 mouse model of Huntington's disease